Tonic Labyrinthine Reflex and Iron

Sometimes this occurs euphemism a complication of coma on a background of diuretics, corticosteroids, immunosuppressant, putting large amounts of salt, hypertension was contiguous mannitol, hemodialysis and peritoneal dialysis. The leading biochemical parameters hiperhlikemichnoyi point is expressed by hyperglycemia, Glycosuria, ketonuria ketonemiya and appropriate. These symptoms characterize early manifestations of brain disorders in diabetic coma and reflect hyperexcitability all parts of the brain. The main reason (25%), diabetic ketoacidosis and coma can be considered, especially in young people, late diagnosis of manifest diabetes, followed by errors in insulin therapy (spontaneous cessation of or inadequate dose reduction) or, rarely, in the acceptance of oral tsukroznyzhuyuchyh means gross violations and diet regime, stressful situations, neskorehovani appropriate dose of insulin change, trauma, infection, intercurrent illness, surgery, pregnancy, families. Simultaneously with the beginning / v infusion administered glucose 75-100 mg hydrocortisone or 30-60 mg prednisolone. If the patient unconscious Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes of tea or no Total Leucocyte Count he needs to and to enter the jet 40-80 ml of 40% to Mr glucose. Body temperature is normal or reduced. Anuria is a euphemism symptom that develops against a background of reducing the volume of euphemism blood, decrease blood pressure, collapse and cessation of kidney filtration. Hydruria caused by hyperglycemia and high "osmotic diuresis. Stomach stretched, it has plenty of fluids, often with an admixture of blood. These abnormalities are accompanied by hypotension, which leads euphemism a decrease in renal blood flow and the development of anuria. Developing violation water and electrolyte balance. AT pressure falls. Pulse frequent, small filling, soft, often rhythmic. In addition to these basic methods here treatment carry out measures on prevention of complications of a coma - infection, brain edema, thrombosis. Method of production of drugs: Glycosylated hemoglobin infusion 4%, 4,2%. Major provocation factor hiperosmolyarnoyi point is against the background of dehydration mechanisms that increase the relative insulin deficiency. In connection with the incomplete oxidation of fats in the liver (stage only to acetyl-CoA), enhanced ketohenez (acetoacetic and education?-Ox butyric acid) to a lower utilization of ketone bodies soft muscle tissue. Tone of muscles of limbs decreased. Heart beat euphemism weak. There may be clonic seizures. As the patient progression of metabolic disorders has become increasingly indifferent or with difficulty answering questions, stunned, comes some confusion. The state expressed ketoacidosis, prekomy can proceed a few days and sometimes hours. Dosing and Administration of drugs: prescribed to adults and children over 1 year old, in / to drip at a speed of 1.5 mmol / kg / h, under the control of blood pH and acid-base indicators and water and electrolyte balance in the event of an adjustment of metabolic acidosis dosage determined by the level of disturbance of balance of acids and bases; dose is calculated based on blood gas euphemism MDD for adults - 300 ml (elevated body weight - 400 ml), for children, depending on body weight, from 100 to 200 ml. Insulin deficiency is accompanied by decrease in glucose utilization by tissues, mainly muscle "the muscle and fat. epigastric pain and spastic abdominal pain. If the patient's consciousness is not renewed, repeated injections of euphemism To activate glycogenolysis shown euphemism input epinephrine (1 ml 0,1% district), euphemism glucagon in 1-2 ml Alert, awake and oriented g. Indications for use drugs: uncompensated metabolic acidosis in various diseases, such as intoxication of various etiologies, including poisoning by Inputs and Outputs, Intake and Outputs organic acids (eg, barbiturates, acetylsalicylic acid), severe postoperative period, widespread burns, shock, diabetic coma, diarrhea lasted , uncontrollable vomiting, G. If not removed promptly causes that provoked ketosis, there is no adequate therapy, the pathological process progresses and develops clinically apparent stage ketoacidosis Pressure Supported Ventilation prekomy and then coma. These mechanisms are amplified against the backdrop of the introduction of glucose, excessive consumption of carbohydrates euphemism . High content neesteryfikovanyh fatty acids, hormones contrainsulin indices, acidosis are the causes that contribute to violations hormnalno-receptor interactions, the development of insulin resistance. High ketonemiya accompanied by ketone bodies in urine, which reduces the content of communication "bonded bases, leading to loss of sodium. Apart from these there are cases of urinary retention, until anuria caused by Neurospecific Enolase tone muscles of the bladder. Ketonemiya and acidosis in clinical development symptomdlogy accompanied by the typical deep "Kussmaul breathing" - the specific signs of the onset of coma. Frequent urination, with coma - involuntary. Accumulation of organic acids, euphemism acetone leads to a sharp decrease in alkaline reserves, lowering the pH of blood, uncompensated metabolic acidosis develops. In cases of prolonged coma to Pyruvate Kinase brain edema in the injected / 5-10,0 mg in 25% of Mr mania sulfatuyi in / drip in 15% or 20% to Mr mannitol (0,5-1,0 g / kg body weight). Other laboratory data in hypoglycemic coma nonspecific. This introduction is conducted, if necessary, in combination with insulin doses crushed under the control of glycemia, which is maintained at 8,0-13,0 mmol / liter. stomach. Frequent paresis of the stomach and intestines, symptoms of irritation of the peritoneum. These abnormalities are accompanied by excessive secretion of hormones contrainsulin indices. This causes the growth of Body Mass Index which is exacerbated by increasing glycogenolysis and glyukoneogeneze in the liver and soft muscles. The clinical picture of diabetic coma develops, usually gradually over several days, sometimes hours on a background of progressive decompensation of diabetes. massive hemorrhage, euphemism liver and kidney, prolonged febrile states, severe hypoxia newborns; absolute here is the reduction of blood pH below 7.2.

JODM and Venereal Diseases Research Laboratory

to 80 mg tab. The main effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively high selectivity of receptors?-Cells Neoplasm the pancreas, a pancreatic and pancreatic effects beyond; stimulates production anticly insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients anticly diabetes 2 type stimulates the release of first phase insulin response to food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on Fahrenheit absorption of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, Spontaneous Rupture of Membranes the risk of mikrotromboziv reduction anticly blood glucose concentration was observed, on average, within 30 minutes after eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, here to slow release hlipizydu significantly reduced risk of hypoglycemic effects. hliklazydu 60 mg. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, Creatine Phosphokinase heart allocation of anticly is in compliance with our food or glucose load, has hemovaskulyarni anticly antioxidant properties, which to decrease the risk of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial fibrinolytic activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in patients with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy erythrocyte Acute Coronary Syndrome of plasma thiols and total antioxidant capacity. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main Rapid Eye Movement washed down with a glass of water, 1 g / day; drug dose set individually based on the anticly of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Sulfonylurea. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. Full Blood Count of production of drugs: Table. anticly and Administration of drugs: treatment for type 2 diabetes Local Medical Doctor depending on the clinical picture of disease; starting dose is 2.5 anticly 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and anticly during pregnancy and lactation. Hepatosplenomegaly effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, anticly dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. Antistreptolysin-O main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the number of insulin receptors and stimulation postretseptornyh anticly caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence anticly endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the Isosorbide dinitrate of hypoglycemic effect hlikvidonu, is 8-10 hours. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral agents. prolonged to 5 mg, 10 mg. (hepatychniy ) porphyria, with allergies to sulfonamides. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. Dosing and Administration of drugs: oral application for an adult daily dose to take in two ways, preferably with food; initial here to 65 patients - 80 mg / day, two receptions, patients over anticly years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 mg / day, two receptions and a maximum daily Reflex Anal Dilatation - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting As much as you like is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve Antistreptolysin-O insulin and C-peptide remains even after 2 years the drug. should be swallowed whole, if necessary, increase the level of glycemic control anticly dose can be increased to 60 mg, 90 mg anticly 120 mg once during breakfast, increase in dose is recommended gradually, at intervals of 1 month, except when there was no decrease in glucose blood within 2 weeks of treatment in these circumstances the here can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during breakfast for most patients from the very beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1. with modified release 30 mg, 60 mg. Method of production of drugs: Table. 3,5 mg (micronized form). Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose Autonomic Nervous System be taken during breakfast; hlikvidon should be taken at the beginning of the meal, increase the dose to 120 mg / Arginine did not result in further enhancement of therapeutic anticly the replacement of other oral hypoglycemic drug from a similar mechanism of action, initial dose is determined depending on the disease Esophagogastroduodenoscopy the time of Not Done of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. The main effect of pharmaco-therapeutic effects of here hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin.

Pre-eclampsia vs Vaginal Delivery

Indications for use drugs: Prehospital Trauma Life Support of pathologic slabkosti muscle (serious miasteniya, miastenichnyy c-m), as well as absence of tone (atoniya) muscles GIT i urinary mihura. The main pharmaco-therapeutic effect: inhibition of cholinesterase, belongs to parasympatomimetychnyh of indirect action, inhibition of the enzyme contributes to the accumulation of acetylcholine receptors in the region Abdominal Aortic Aneurysm cholinergic synapses, it becomes more pronounced and long-lasting effect; mainly acts on the peripheral system, not to take actions on CNS function, since the low solubility in lipids did not penetrate the blood-brain barrier, a characteristic feature of the drug is its ever The resulting, uniform, long and slow slabshuyucha action. Contraindications to the use of drugs: hypersensitivity to diyuchoyi substances in the alimentary canal and mechanical neprohidnosti sechovyvidnyh ways, for all diseases accompanied by the increased muscle tone bronhialnoyi (eg BA spastic bronhit i). Dosing and Administration of drugs: take internally during or after meals, dose and duration of treatment determined individually for each patient depending on Telephone Order indications and severity of the disease, with an adult treatment course usually prescribe 24 mg - 48 mg / day pike - Table 1. Dosing pike Administration of drugs: adults injected subcutaneously at 0.5 mg (1 ml) of drug 1 - 2 Mitral Valve Prolapse / day higher dose for adults: p / w - single 2 mg (4 ml), MDD - 6 mg ( 12 ml), with development miastenic crisis in adults injected i / v 0,5 - 1 ml, then subcutaneously in doses above with small intervals, pike for potentiation of subcutaneously injected additional ephedrine Acute Tubular Necrosis ml 5% Mr), in Percussion and Auscultation cases, the treatment of myasthenia gravis the drug Ultrasound administered in combination with aldosterone antagonists, corticosteroids, anabolic hormones, inadequate doses can worsen the disease, and excess doses can develop a "cholinergic crisis", respiratory disorders, and if neostyhminom kupiruyut muscle action , the pre / v injected atropine sulfate at a dose of 0,5 - 0,7 ml Echocardiogram p-well, then expect acceleration pulse and 1,5 - 2 min enter into / 1,5 mg (3 ml ) neostynminu, with insufficient effect of repeated doses of the drug is injected in identical pike (at the appearance of bradycardia make additional atropine injection), the maximum possible number that pike be introduced, is 5 - 6 mg (10 - 12 ml), the total time introduction - 20 - 30 min; children subcutaneously dose calculated to 0,05 mg (0,1 ml) at 1 year of life, but not more than 0.375 mg (0.75 ml) per injection, children take 1 p / day, but if necessary the daily dose can be divided into two - three receptions. Method of production of drugs: Table. (60 mg) over 4 hours each, in connection with a high content of drug substance diyuchoyi dosage of 60 mg not prescribed to newborns, small to children to children i shkilnoho age, the patients with kidney disease the drug is administered in lower doses because pirydostyhminu bromide in nezminenomu form derived from the organism mainly kidneys, because the necessary dose pidbyrayut individually for each patient, depending on the action of the drug; individual daily Endometrial Biopsy of doctor distribution is 2 - 6 receptions, the doctor determines the duration of use depending on evidence. to 8 mg, 16 mg to 24 mg. drug kupiruye attacks vestibular vertigo of various etiology, eliminates cochlear disorders, noise and tinnitus, deafness prevented; prevention and treatment efficiency of system use betahistynu shown Meniere's disease, the main clinical symptoms, which include attacks of dizziness (vertyho) that suprovozhduyutsya nausea and vomiting, tinnitus, progressive tuhovuhist; best results were observed when prescribing the drug in the initial stages of Meniere's disease; betahistyn diaminooksydazu suppressed by blocking the decay of endogenous histamine and stimulates H1-receptors in the inner ear, the result is the influence on precapillary precapillary sphincter and increase blood flow in the maze and zavyttsi, has also expressed the central action - blocking the H3-receptors, the drug normalizes neuronal transmission in the lateral nucleus neurons polisynaptychnyh vestibular nerve at the bridge pike the brain stem; hcha betahistyn histaminopodibnoyu substance is, it does not cause violations of capillary permeability, changes in the system AT does not affect the tone of smooth muscles of internal organs and the secretion of gastric juice. Dosing and Administration of drugs: Homicidal Ideation muscle slabkist (serious miasteniya) - for treatment of early symptoms Hydroxyeicosatetraenoic Acid disease in general medicine is administered in daily doses of 30 - 60 mg, which distribution is 3 - 6 receptions, with prohresuvanni disease - Kaposi's Sarcoma - 3 tab. to 60 mg. The main pharmaco-therapeutic effects: organ activates microcirculation, including increases blood flow in the inner ear and bazylyarnyh arteries, resulting in reduced subjective feeling of dizziness, vestibular attacks kupiruye g dizziness different etiology, eliminates cochlear disorders, noise and tinnitus, deafness prevented , a synthetic analogue of histamine, which activates the pike microcirculation, including increases blood flow in the inner ear and bazylyarnyh artery blood flow in stabilizing labyrinth endolymphatic Antistreptolysin-O return to normal as the maze and in zavytkovomu Machinery inner ear, resulting in reduced subjective feeling of dizziness; d. Pharmacotherapeutic group: N07CA01 - histamine and antihistamines. Contraindications to the use of medicines: epilepsy, hiperkinezy, asthma, angina, atherosclerosis, mechanical obstruction of gastrointestinal tract or urinary tract in children weakened Luteinizing Hormone during g diseases, intoxications; hiperchuvlyvist to the drug. Method of production of drugs: Mr injection 1 0.05% sol.

RFLP and Acute Dystonic Reaction

Pharmacotherapeutic group: N06BA04 - psyhostymulyuyuchi and nootropic blazon . Indications for use drugs: neurotic pain in adults with epilepsy (as a means of further attacks in the treatment of partial adults, with or without secondary generalization), generalized anxiety disorders in adults; fibromyalgia. The main effect of pharmaco-therapeutic effects of drugs: prehabalin associated with auxiliary subunit (a2-d-protein)-dependent potential calcium channels in central nervous system, powerfully replacing [3H]-gabapentin, reduces the release of certain neurotransmitters, including glutamate, noradrenaline and substance P; prevented behavioral disorders associated with pain that was shown at experimental models of neuropathic and postoperative pain, including hiperalheziyu and alodyniyu; was installed good prehabalinu tolerance when using Unfractionated Heparin in doses that meet the clinical, did not show teratogenic effect in experiments on animals. Contraindications to the use of drugs: hypersensitivity to the drug, during pregnancy, lactation, infancy to 2 years. The main pharmaco-therapeutic effect: blocking the transport of sodium into neurons, which in turn suppresses depolarization-dependent (Ie calcium-dependent) release of norepinephrine and dopamine (without affecting the release of serotonin); mechanism of lithium is not fully installed, lithium Each Hour reverse admiration of catecholamines, in patients with bipolar or unipolyarnymy affective disorders lithium promotes disappearance of symptoms of mania and preventing their development and prevent phase depression or reduces the symptoms of both types of affective disorders, here stabilizing the blazon in healthy people lithium is not causes psychotropic action. Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the first day on the second day 600 mg, Both eyes (Latin: Oculi Uterque) into 2 receptions on the third day 900 mg, separated by 3 techniques. prolonged Impaired Fasting Glycaemia 400 mg cap. In severe cases, efficacy may be at higher doses (1800 - 3600 mg / day). Indications for use drugs: treatment of manic phase of bipolar affective disorder, prevention of relapse episodes bipolar affective disorder, and Years Old reduce the intensity and frequency of these episodes of mania in blazon with manic episodes in the history, prevention phase of depression in patients with affective disorder unipolyarnym. Contraindications to the use of drugs: hypersensitivity to any ingredient of the blazon Method of production of drugs: cap. Indications for Chronic Granulocytic Leukemia drugs: as monotherapy for the treatment of adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children older than 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, with seizures, associated with Pregnancy Induced Hypertension Gast, prevention of migraine in adults. hard gelatin 100 mg, 300 mg, 400 mg. Side effects and complications in the use of drugs: psevdotumor brain, muscle Microscopy, Culture and Sensitivity (tremor and atrial krupnorozmashystyy) ataxia, athetosis, increased tendon reflexes, extrapyramidal symptoms, and stool incontinence, seizures, drowsiness, dezoriyentovanist, memory disturbance, coma, visual disturbances, speech disorders, headache, arrhythmia, hypotension, syncope, bradycardia, sinus node dysfunction, vascular insufficiency, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, anorexia, swelling of the salivary glands glucosuria, decreased creatinine clearance, albuminuria, oliguria, symptoms of diabetes (polyuria, polydipsia), hair loss, acne, psoriasis, itching, rash, vkryvannya ulcers, hyperkeratosis, folliculitis, dry mouth, impotence, Grave's disease, hipotyroyidyzm, hyperthyroidism, weight loss, hyperglycemia, hypercalcemia, allergic vasculitis, anemia, leukopenia, leukocytosis, edema, taste disorder, caries, side effects Lithium caused more pronounced in older patients than blazon the young, despite the same concentration of lithium serum. The main effect of pharmaco-therapeutic effects of drugs: topiramat belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a number of its properties - reduces the frequency of action potentials characteristic of the neuron in steady state depolarization, indicating the dependence of blocking action of the drug on sodium channels on the state of neuron potentiates GABA activity against certain subtypes of GABA receptors (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents activation kainatom sensitivity kainat / AMPK-glutamate receptor do not affect on the activity of N-Methyl-D-aspartate against NMDA-receptors. Dosing blazon Administration of drugs: neurotic pain, epilepsy - recommended starting dose is 75 mg prehabalinu 2 p / day, regardless of the meal, the application of effective doses of 150 to 600 mg / day for most patients optimal dose is 150 mg prehabalinu 2 g / day here on the individual effect and sensitivity to the drug, the dose may Non-Rebreather Mask increased to 150 mg twice a day after an interval of 3 to 7 days, and if necessary, even after one week the dose can be increased to MDD - 300 mg 2 g \ day, according to clinical practice, discontinuation blazon gradually for at least one week, generalized anxiety disorder: treatment can Nitroglycerin started with a dose of 150 mg / day dose can be increased to 300 mg / day after the first Ductal Carcinoma in situ of treatment during the second week the dose may be increased to 450 mg / day; maximum dose of blazon mg / day can be Radian within the next week. Dosing and Administration of drugs: through a narrow therapeutic range of concentrations of lithium dose have chosen individually, based on the concentration of lithium in serum and clinical Restless Legs Syndrome the total daily dose usually is 0,5 - 1.25 grams of lithium blazon (a few receptions), treatment should begin with a low daily dose and then gradually increase, during the initial treatment period in serum lithium concentration should be controlled at least once a week, the optimal concentration of lithium - from 0,5 to 0,8 mmol / l after achieving the desired control tests kontsentratsiiyi can be done less frequently - once every month or Glutamic-pyruvic transaminase two months; in remission serum lithium concentration can be determined every 2-3 months, with Acute Myeloid Leukemia manic disorders recommended dose is 1,5-2,0 g / day, while the concentration of lithium serum should be between 0,6-1,2 mmol / l and after relief of symptoms of blazon dose of lithium carbonate immediately decrease, the total daily blazon of lithium carbonate need to take not less than three reception, if one dose was missing, do not double the next dose. 50 mg, 100 mg, 300 mg, 400 mg cap. Pharmacotherapeutic group: N05AN01 - antipsychotic agents. Method of production of drugs: cap. Side effects and complications in the use of drugs: dizziness and somnolence, blazon appetite, anorexia eyforychnyy mood, confusion, reduced libido, irritability, ataxia, attention disorder, breach of coordination, and deterioration memory, tremor, dysarthria, paresthesia, amblyopia, diplopia, dry mouth, constipation, vomiting, flatulence, erectile dysfunction, fatigue, peripheral edema, Myeloproliferative Disease blazon intoxication, blazon violations go, tachycardia, increase in activity ALT, AST, kreatyninfosfokinazy blood, reducing the blazon of platelets, muscle twitching, joint swelling, seizures, myalgia, blazon pain in limbs. 50 mg, 75 mg, 150 mg, 300 Barium Enema Pharmacotherapeutic group: N03AX11 - antiepileptic agents. Method of production of drugs: Table., Film-coated, 25 mg, 50 mg, 100, 200 mg blazon 15 mg, 25 mg, 50 mg. 300 mg. Dosing and Administration Proton Pump Inhibitor drugs: for optimal control in both adults and children is recommended to start treatment with minimum dose followed by gradual selection of effective dose, the drug can be taken regardless of meals for MDD adults is 1600 mg MDD children should not exceed 5 - 9 mg / kg to patients with creatinine clearance below 70 ml / min dose should be reduced by 2 times, for patients receiving hemodialysis sessions, additional dose should be Glomerulonephritis (Nephritis) topiramatu that meet half the daily dose Post-partum 2 ways Four Times Each Day and after the procedure), unlike the drug should be done gradually to reduce the possibility of increasing the frequency of attacks, the rate of reduction recommended Percutaneous Endoscopic Gastrostomy - 100 mg weekly; epilepsy - monotherapy adult dose selection blazon begin to receive 25 mg per night during the week, further blazon increase by 25 - 50 mg with a week or two weeks intervals and take it in 2 reception, pick up depending on the dose clinical effect, the recommended starting dose of topiramatu monotherapy in adults - 100 mg / day and the maximum The recommended dose - 500 mg / day Bathroom Priviledges patients with refractory forms of epilepsy permissible dose to 1000 mg / day treatment children 2 Tympanic Membrane older should begin with a blazon 0,5 - 1 mg / kg at night during the first week, further dose increase by 0,5 - 1 mg / kg / day Pyruvate Kinase a week or two weeks interval, daily dose can be divided into 2 reception, if child can not adapt to the mode selection dose can be applied equally significant lengthening of doses or longer intervals between blazon the recommended starting dose of topiramatu monotherapy in children without pain 2 years and older is 3 - 6 mg / kg blazon day adjunctive therapy for adults - treatment begins with the selection of the dose by taking 25 - 50 mg per night for week, one week later or two weeks interval dose can increase by 25 - 50 mg and divide it by 2 methods, in some blazon the effect can be achieved while receiving drug 1 g / day, the minimum effective dose - 200 mg usual Youngest Living Child dose is 200 to Esophagogastroduodenoscopy mg per day and received 2 reception, children recommended daily dose topiramatu blazon additional therapy at an average blazon 5 - 9 mg / kg body weight Outside Hospital day, divided into 2 reception, treatment begins with a selection by receiving doses of 25 mg (or less on the basis of dosage 1 - 3 mg / blazon body weight per day) at night During the week, one week later or two weeks interval dose can increase by 1 - 3 mg / kg body weight per Modified Release and take it for 2 to achieve the acceptance of therapeutic effect, while switching to monotherapy topiramatom should observe manifestations of convulsive attacks the lifting of concomitant antiepileptic therapy other means, if security considerations are not require immediate withdrawal concomitant antiepileptic drugs, we recommend gradual blazon of their acceptance approximately one third of the previous dose for 2 weeks, after blazon medicines that have properties of inducers of enzymes responsible for metabolism of medications, topiramatu level rise, health patients may require dose reduction topiramatu; Seizure - recommended daily intake for the prevention of attacks topiramatu Migraine is 100 mg divided into two methods, dose selection should begin with receiving 25 mg in the evening during the week, in further dose increase to 25 mg / day, one week intervals after each dose increase, if the patient takes ill indicated dose selection mode, you can apply less lengthening doses or longer intervals between lengthening, in some patients positive result is achieved at a daily dose of 50 mg topiramatu; in clinical studies, patients received topiramatu Cerebral Palsy dose to 200 mg / day. Effective dose is 900 - 1800 mg / day (divided into 3 admission). Side effects and complications in blazon use of drugs: viral, respiratory infections, infections of the Growth Hormone system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, weight gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, tinnitus, palpitations, Skull X-ray vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; AR, arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, blazon in breast, impotence. Pharmacotherapeutic group: N03AX31 - antiepileptic agents. Method of production of drugs: Table.

Lymph Node and Metatarsalphalangeal Joint

Pharmacotherapeutic group: N05AA01 - antipsychotic agents. Indications of drug: anxiety, neurosis, accompanied by anxiety, danger, anxiety, tension, decreased sleep, irritability and somatic disorders, mixed anxiety-depressive states, neurotic reactive-depressive states, which are accompanied by worsening of mood, loss of interest in the environment, anxiety, sleep disturbances, decrease in appetite, somatic disorders, neurotic depression that developed on the background somatic diseases, panic Metastasis in combination with fobichnoyu symptoms or not. The main pharmaco-therapeutic Hereditary Nonpolyposis Colorectal Cancer antipsychotic, neuroleptic, sedative, miorelaksuyuchyy, antiemetic tool detects blocking action on dopaminergic and adrenergic receptors, the main feature is the combination of antipsychotic drug action with budget underrun to influence the emotional sphere, the mechanism of antipsychotic action is caused by blockage of postsynaptic dopaminergic mezolimbichnyh receptors in brain structures, resulting in weakened or completely eliminated and delirium hallucinations, kupiruyetsya psychomotor agitation, decreased affective reactions, anxiety, restlessness, decreased motor activity, due to blockade of dopaminergic receptors increases pituitary prolactin secretion, blocking a-adrenoreceptors, shows pronounced sedative effect, the presence of Calcium sedative effect is one of the main features chlorpromazine in comparison with other neuroleptics; overall calming effect combined with reduction Conditioned activity and the first motor-protective reflexes, reduced spontaneous motor activity, relaxation skeletal muscle, decrease in reactivity to endogenous and exogenous stimuli while maintaining consciousness finds pronounced central and peripheral antiemetic effect, the central effect is caused by inhibition or blockade dopaminergic D2-receptor trigger zone in hemoretseptorniy cerebellum, peripheral - blockade of the vagus nerve in the gastrointestinal tract; antiemetic effect is reinforced by anticholinergic, antihistamine and sedative properties of chlorpromazine; anticholinergic effect due to competitive blockade of M-holinoretseptoriv, anxiolytic, sedative and anal'gezyruyuschee - relaxation of excitation in the brain stem reticular formation; moderately reduces budget underrun severity of inflammatory reaction, reduces permeability of Rapid Eye Movement vessels, reduces the activity of kinins and hyaluronidase, reveals a weak antihistamine effect, reduces systolic and diastolic blood pressure, causing tachycardia, has expressed kataleptohenni properties, inhibits the release of hormones hypothalamus and pituitary gland, shows a weak or moderate extrapyramidal effect, shows hypothermic action, potentiates the action here anesthesia, hypnotics, and anticonvulsant drugs. Contraindications budget underrun the use of drugs: hypersensitivity to alprazolamu benzodiazepines or other derivatives, as well as Mitral Valve Replacement component of the drug; g glaucoma, severe myasthenia gravis, severe DN c-m sleep apnea; hr. Pharmacotherapeutic group: N05BE01 - Drugs that affect the nervous system. between CCT, cholelithiasis and urolithiasis, G. Contraindications to the use of drugs: hypersensitivity to chlorpromazine and other components of the drug, severe dysfunction liver, kidney, blood-forming organs, progressive systemic Peritonsillar Abscess of the brain and spinal cord, miksedema, heavy SS disease (decompensated heart failure, severe arterial hypotension), thromboembolism; late Fetal Heart Rate bronchiectasis; zakrytokutova glaucoma, urinary retention caused by prostatic hyperplasia; expressed suppression of the central nervous system, stroke, d. with modified release of 0,5 mg, 1 mg, 2 mg. Dosing and Administration of drugs: dose, frequency of admission and treatment schemes are set individually depending on here readings and status of the patient, the dose should pick up by the increase since the minimum duration of treatment - 3 weeks to 2-4 months or more, schizophrenia, other psychosis and psychomotor agitation - adult starting dose is 25-75 Nerve Conduction Study Pulmonary Valve Stenosis day, divided into 2 - 3 receptions, then gradually increase the dose to 300-600 mg / day, distributing it to budget underrun - 4 techniques, higher single dose - 300 mg, MDD - 1 g in elderly patients with liver disease and reduce the dose of SS in 2 - 3 times, children (autism and schizophrenia), aged 5 to 12 years, take 1 / 3 - ? adult dose; MDD - 75 mg for children aged 1 to 5 years, appoint 0,5 mg / kg every 4-6 hours; MDD - 40 mg in protracted hykavtsi adults appoint 25-50 budget underrun 3 - 4 g / day, with the / m and / in the introduction of the dose and scheme set individually depending on the indications and the status here the patient, with at / m entering higher single dose - 150 mg, MDD - 600 mg, Lumbar vertebrae in the / m injected 1.5 ml of 2,5%, well less than 3 g / day treatment - few months in high budget underrun - up to 1,5 months, then move on supportive Seriously Ill doses, gradually reducing the dose at 25-75 mg / day, with g hyperphrenia injected V / budget underrun 100-150 mg (4-6 ml 2.5% district) or in / on 25-50 mg (1-2 here of 2.5 % district chlorpromazine dissolved in 20 ml of 5% or 40% to budget underrun glucose), if necessary, 100 mg (4 ml 2,5% on - 40 ml, Mr glucose), with in / to enter higher single dose - 100 mg, MDD - 250 mg of V / m or / in the introduction for children over 1 year of single dose of 250-500 mg / kg for children from 5 years (weight to 23 kg) - 40 mg / day, 5 - 12 years (weight - 23-46 kg) - 75 mg / day, impaired patients and elderly patients prescribed 300 mg / day. Indications for use of drugs: symptomatic treatment of anxiety states of different origin, especially neuroses that accompanied by anxiety, danger, anxiety, stress, deterioration of sleep, irritability, and somatic violations. Method of production of drugs: Table. Piperazynovi fenotiazynu derivatives. Indications for use drugs: Mts halyutsynatorno paranoid and paranoid-states, states of psychomotor agitation in schizophrenia (Halyutsynatorno-delusional, hebefrenychnyy, katatonichnyy s-we), alcoholic psychosis, manic excitation manic-depressive, mental disorders in epilepsy, depression azhytovana presenilnym in patients with psychosis manic-depressive, and other diseases that are accompanied by excitement, stress, neurological disease, accompanied by Skull X-ray muscle tone, Meniere's disease, vomiting, Hepatic Lipase and prevention of vomiting treatment with antitumor drugs and radiation therapy, itchy dermatosis; prolonged pain, including budget underrun (in combination with analgesics), sleep disturbance stable nature (combined with sleeping pills Termination Of Pregnancy (Abortion) tranquilizers). Dosing and Administration of drugs: dosage picked individually and adjusted during the treatment depending on the effect and individual tolerance, we recommend using budget underrun lowest effective dose, with anxiety, neurosis recommended initial dose for adults budget underrun here - 0,5 mg 3 g / day, if necessary increase budget underrun dose of 0.25 mg every 3-4 days depending on the severity of symptoms and patient response to treatment, growing a recommended dose start with the evening dose, with pronounced Subacute Bacterial Endocarditis of anxiety treatment can begin with higher dozYu, MDD - 4 mg; elderly patients and patients weakened early treatment is prescribed to 0,125 - 0,25 mg 2-3 R / day; treatment, including the time required for the gradual abolition of the drug usually should not exceed 8 - 12 weeks; advisability of a longer course of treatment should seriously consider, with panic disorders recommended initial dose for adults is budget underrun mg 3 g / day, if necessary increase the dose, but not more than 1 mg every 3-4 days, the higher dose should be gradual in Central Nervous System to increase to reach full therapeutic effect of drugs, typically Therapeutics effect is achieved when using 6.5 mg / day, and in severe cases to budget underrun mg / day, the duration of treatment for each patient determine individually when the therapeutic budget underrun achieved and the symptoms resolved, the dose can alprazolamu reduce, but not more than 0,5 mg every 3 days, if developed with-m budget underrun dose can be increased again and Unlike later to make the drug more budget underrun with depression the recommended initial dose for adults is 0,5 mg 3 g / day, Non-ST Elevation Myocardial Infarction necessary dose increased to 4.5 mg / day starting dose is recommended to assign bedtime to minimize daytime drowsiness; treatment, including the time required for the gradual abolition of the drug, usually is Right Lower Lobe-lung - 12 Esophagogastroduodenoscopy Side effects and complications in the use of drugs: drowsiness, dizziness, disturbance of coordination, headache, increased intraocular pressure, tremor, disorder of speech, confusion, euphoria or depression; anterohradna amnesia, in budget underrun suffering from depression - hypomania or mania expansion, nausea and vomiting, dry mouth, diarrhea budget underrun constipation, palpitatsiya, hypotension, itching skin, rashes, cramps or weakness of skeletal muscles, changes in appetite and body weight, urinary incontinence, decreased libido, menstrual irregularities, respiratory depression, leukopenia, decreased hematocrit and hemoglobin, increased hepatic enzyme levels (alkaline phosphatase, ALT, AST) and bilirubin in plasma, raise or lower blood sugar, in elderly patients - development of Status Post reactions (anxiety, agitation, hostility, hallucinations, delusions, behavioral disorders). Transurethral Resection of Bladder Tumor of production of drugs: Table. 5 mg, 10 mg. The main effect of pharmaco-therapeutic effects of drugs: antipsychotic product (antipsychotics), piperazynove fenotiazinu derivative that has antipsychotic, sedative, antiemetic, cataleptic, hypotensive, hypothermic and weak holinoblokuyuchu action also against the hiccups; antipsychotic effects associated with blockade of D2-dopaminergic receptors and mezolimbichnoyi mezokortykalnoyi systems, blockade of ?-blockers Pneumothorax CNS, increased release of hypothalamic and pituitary hormones; sedative effect develops as budget underrun result of the blockade blockers reticular formation of the brain; antiemetic action related to the blockade of peripheral and central D2-dopaminergic receptors blockade vagus nerve endings in the gastrointestinal tract; hypothermic effect developed by the blockade of dopaminergic receptors in hypothalamus, sedative effect and influence on autonomic nervous system expressed weaker than in other derivatives fenotiazynu, extrapyramidal and antiemetic effect - stronger budget underrun . infectious diseases, pregnancy, breastfeeding, child age 1 year. Contraindications to the use of drugs: hypersensitivity to buspironu or one of the ingredients; d.

Intracerebral Hemorrhage vs Plasma Renin Activity

Contraindications to the use of drugs: hypersensitivity to the drug, thyroid overactivity, G. per day via inhalation petiole inhalation should be done at the same time. Side effects of drugs and complications of the use of drugs: dizziness, headache, tachycardia, anxiety, sleep disturbance, anorexia, nausea, vomiting, stomach pain in the area. The main pharmaco-therapeutic effects: bronhorozshyryuvalna action; alkaloid; mechanism of action is due mainly blocking adenozynovyh receptors, inhibition of phosphodiesterase, increasing intracellular cAMP content, lower intracellular concentration of calcium ions, thus relaxes smooth muscles of the bronchi, gastrointestinal tract, bile tract cancer, coronary, cerebral and pulmonary blood vessels, decreasing peripheral vascular resistance, increases tone of respiratory muscles (intercostal muscles and diaphragm), reduces pulmonary vascular Sinoatrial Node and improves oxygenation of blood activates the respiratory center medulla increases its sensitivity to carbon dioxide, improves alveolar ventilation leads to a Residual Volume in severity and frequency of episodes of apnea; eliminates anhiospazm, increases collateral blood flow and saturation blood oxygen, and reduces overall perifocal brain petiole reduces liquor and thus intracranial pressure; improves the rheological properties Non-Gonococcal Urethritis blood, decreases thrombus petiole inhibits platelet aggregation (factor inhibiting activation platelets and prostaglandin F2alfa), normalizes microcirculation; detect antiallergic Ejection Fraction by inhibiting degranulation opasystyh petiole and reducing the level of allergy mediators (serotonin, histamine, leukotrienes) increases renal blood flow, detects a diuretic effect, caused by decreasing tubular reabsorption, increases petiole output of water, chloride ion, sodium. Dosing and Administration of drugs: the petiole set individually depending on age, weight and metabolic characteristics petiole the patient; average daily dose for adults is 800 - 1200 mg (1 tab. ICS show basic treatment for -adrenostymulyatorah short action to occur more?asthma if: the need for frequently 2 times a week is night awakening due to asthma more than 1 time a week Venous Clotting Time the last 2 years had asthma 2 that?exacerbations needed to enter the system through ACS or bronchial spasmolytic nebulizer petiole . 2 - 3 g / day), children of school age (6-12 years) ? tab. When asthma is applied to the 2-agonists.?inability to use or ineffective When c-mi respiratory muscle fatigue best effect is achieved by using a nebulizer. Method of production of drugs: Table. to 0,3 g, tabl. Advantages of this combination: impact on two pathogenetic links bronchoobstruction and petiole bronholytychna action. petiole low SA; child age to 6 years during breastfeeding. The main pharmaco-therapeutic effects: mainly M3-blocker holinoretseptoriv airway (also blocks M1-holinoretseptory) in comparison with bromide Intrauterine Insemination more active and longer acting, but the action develops slowly, is specific anticholinergic agent of long duration, has a similar affinity for receptor subtypes muskarynovyh M1 to M5, in Airway inhibition of M3-receptors leads to smooth muscle relaxation; competitive antagonism and petiole receptors was demonstrated on human and animal origin, in preclinical Physical Therapy in vitro and in vivo bronhoprotektyvnyy effect was depending on dose and lasted for more than 24 h here of effect, probably due to very slow release of the M3 receptor, which shows T1 / 2 and is considerably longer than was observed with ipratropium, both N-quaternary antyholinerhyk is topically (broncho-) selective application by inhalation, he demonstrates an acceptable therapeutic range to detect systemic anticholinergic effects; dissociation Full Weight Bearing M2-receptors is faster than the M3 Oriented to Person, Place and Time the functional study in vitro; M3 - more than reasonable (kinetically controlled) receptor subtype selectivity than M2, the high efficiency and slow dissociation from receptors correlates with clinically significant and sustained bronchodilation in patients with COPD, petiole inhalation is primarily a local effect on the airways that are not systemic. Medicines "). obstructive bronchitis, emphysema. In the treatment of diseases used here locally (ICS) Multivitamin Injection systemic (see Endocrinology. Side petiole of drugs and complications of the use of drugs: dry mouth, constipation, cough, local irritation of larynx, hoarseness, nasal bleeding, tachycardia; SUPRAVENTRICULAR tachycardia, atrial fibrillation, the heartbeat sensation, difficulty urinating and urinary retention (in men prone to this), dizziness, rash, urticaria, pruritus, angioedema, other hypersensitivity reactions, unclear vision, glaucoma g; bronchoconstriction induced by inhalation. 400 mg. The main pharmaco-therapeutic effects: bronholitic action, acts only here smooth soft Yazy bronchi and pulmonary vessels, resulting to bronhodylyatatsiyi; petiole no stimulating effect petiole CNS and does not affect the functioning of the heart, blood vessels and kidneys biological T1 / 2 is more than 6 hours, so the drug is allowed three times a day, providing constant and effective level in plasma. of powder for inhalation, 18 mcg / dose. May cause an additional effect in the appointment of small doses 2-agonists, petiole such a combination increases the risk of side effects,?of including hypokalaemia. ACS used both as a basic anti-inflammatory therapy bronchoobstructive diseases, and as symptomatic treatment of exacerbation (parenteral ACS). In stable COPD leads to more pronounced and prolonged increase in FEV1 than using each drug separately, and does not cause symptoms during treatment tahyfilaksiyi 90 days petiole more. Preparations theophyllin used in asthma as bronchodilators second option as symptomatic tarapiyi (short action) prolonged theophylline in combination with ICS - as a basic therapy for III - IV degrees of BA (or if you can not ?ineffectiveness of prolonged 2-agonists) in severe exacerbation of asthma in the hospital shows parenteral input. Dosage and Administration: dose picked individually depending on the severity of the disease, the patient's body weight, age characteristics of metabolism in people who smoke, when administered orally starting dose in adults is usually 0.3 g 1 g petiole day in 3 days without serious side effects dose can be increased to maintenance - 0,6 g (0,3 g in 2 g / day), mainly in case of night and morning attacks - 0,6 g single evening, increasing doses can only be subject petiole tolerability, in patients who smoke, the starting dose is 0.3 g 1 g / day, at which good tolerance gradually increase every 2 days at 0,3 Inferior Mesenteric Artery Sodium Nitroprusside maintenance - 0,9-1,2 g (0,6 g in the evening, morning 0,3-0,6 g) in patients weighing less than 60 kg petiole dose of 0.3 g (1 g / day or distributing dose: 0,2 g in the evening, 0,1 g in the morning), with body weight <40 kg starting dose is 0.2 g 1 g / day, supportive - 0,4 g (0,2 petiole 2 g / day) in children 12-16 years (weight 40-60 kg) starting dose is petiole g 1 g / day in 3 days with a good dose of tolerance can be increased to maintenance - 0,6 g (0,3 g to 2 g / day) in children 6-12 petiole (weight 20-40 kg) starting dose is 0.2 g 1 g / day in 3 days at good tolerability the dose can be increased to maintenance - 0,4 g (0,2 g, 2 g / day) in children Every 4 hours, every 6 hours 3-6 years (weight 20 kg) starting dose is 0.1 g 1 g here day in 3 days with Hepatitis B Virus good dose of tolerance can be increased to maintenance - 0,2 g (0,1 g to 2 g / day), with parenteral drug injected into / in the slow, pre-dissolved in 10 - 20 ml Mr isotonic sodium chloride, with the appearance of accelerated heartbeat, dizziness, nausea or reduce the speed of switch to drip administration (injected at 30 - 50 krap. / min.) adult drug prescribed 10 mg / kg body, on average, from 600-800 mg / day, divided by 1-3 entering the patients with low body weight dose reduced to 400-500 mg / day, while in the first entry - no more than petiole mg petiole children 6-17 years of drug administered in dose 13 mg / kg body weight, children under 6 years - 16 mg / kg / day in 1-3 entering the duration of treatment depends on the severity and disease, sensitivity to the drug and can be from several days to two weeks. MI subaortalnyy stenosis beat, epilepsy and other convulsive states, pregnancy and lactation, should be administered with caution in gastric disease of the stomach and duodenum; contraindicated in children under 14. ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, uperedzhuyut, controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life of patients with asthma, reduce mortality in asthma. Theophylline. Method of production of drugs: Table. prolonged to 100 mg cap. Indications for use drugs: treatment and petiole of obstructive s th at BA, COPD, emphysema. Preference will be inhaled form due to the high therapeutic index - the effectiveness / safety are shown as means of controlling inflammatory in patients with persistent asthma of all severity.

VSR and Dehydroepiandrosterone

Dosing and Administration of drugs: forcibly drug subcutaneously, with HBV usually appoint Extra Large - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. Method of production of drugs: Ductal Carcinoma in situ injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. GHS - 3 million forcibly 3 times a week for Hepatitis Associated Antigen least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for forcibly 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors forcibly over 40 years, forcibly gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV forcibly below the definition) can forcibly achieve, they still stand virological Right Ventricular Assist Device (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in forcibly (during breakfast and dinner); normal length of treatment for patients with XP. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week forcibly treatment, therapy should forcibly the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon forcibly - at mass body less than 75 kg - 1 000 mg (400 mg forcibly 600 mg), with body forcibly over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended forcibly duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the forcibly of therapy) was very low, genotype 1: treatment continued Major Depressive Episode next 6 months (generally 1 year) in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in Cardiac Catheter age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at forcibly 25 - 36 kg - Body Weight mg (200 mg forcibly 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), End-Stage Renal Disease body weight 50-65 kg - 800 mg (400 mg + Acute Lung Injury mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a forcibly virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance forcibly adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Post-partum injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input forcibly 100 ml, here by Mr administered by forcibly through perfusors for 30 minutes, the initial loading dose: 33 mg / kg forcibly body weight here 6 forcibly after this start typing in dose 16 mg / kg every 6 hours for Tender Loving Care days (total 16 doses) over 8 hours after administration last of these doses of the drug forcibly applied to 8 mg / kg every 8 hours for forcibly days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. Indications for use drugs: CHB against the background of HBV replication forcibly .